Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free PMVP Stock Alerts

PMV Pharmaceuticals (PMVP) Financials

PMV Pharmaceuticals logo
$1.24 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.23 -0.01 (-0.81%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for PMV Pharmaceuticals

Annual Income Statements for PMV Pharmaceuticals

This table shows PMV Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -18 -25 -34 -58 -73 -69 -59 -78
Consolidated Net Income / (Loss)		 -18 -25 -34 -58 -73 -69 -59 -78
Net Income / (Loss) Continuing Operations		 -18 -25 -34 -58 -73 -69 -59 -78
Total Pre-Tax Income 		-18 -25 -34 -58 -73 -69 -75 -80
Total Operating Income		 -19 -27 -35 -58 -77 -80 -85 -86
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 19 27 35 58 77 80 85 86
Selling, General & Admin Expense		 5.04 5.88 11 22 25 24 27 16
Research & Development Expense		 14 21 24 36 52 56 59 70
Total Other Income / (Expense), net		 1.36 1.29 0.51 0.92 3.71 11 11 6.34
Interest Expense		 -1.34 -1.30 -0.65 -0.45 -3.63 -11 -11 -6.34
Income Tax Expense		 0.00 0.01 0.01 0.02 -0.01 0.00 -16 -2.17
Basic Earnings per Share		 ($5.82) ($8.35) ($2.40) ($1.28) ($1.61) ($1.44) ($1.14) ($1.48)
Weighted Average Basic Shares Outstanding		 3.01M 3.04M 14.36M 45.14M 45.59M 48.01M 51.58M 52.54M
Diluted Earnings per Share		 ($5.82) ($8.35) ($2.40) ($1.28) ($1.61) ($1.44) ($1.14) ($1.48)
Weighted Average Diluted Shares Outstanding		 3.01M 3.04M 14.36M 45.14M 45.59M 48.01M 51.58M 52.54M
Weighted Average Basic & Diluted Shares Outstanding		 3.01M 3.04M 14.36M 45.14M 45.77M 51.44M 51.93M 53.33M

Quarterly Income Statements for PMV Pharmaceuticals

This table shows PMV Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -17 -16 -15 -1.21 -19 -23 -17 -21 -21 -18 -18
Consolidated Net Income / (Loss)		 -17 -16 -15 -1.21 -19 -23 -17 -21 -21 -18 -18
Net Income / (Loss) Continuing Operations		 -17 -16 -15 -1.21 -19 -23 -17 -21 -21 -18 -18
Total Pre-Tax Income 		-17 -16 -15 -17 -19 -23 -20 -21 -21 -18 -18
Total Operating Income		 -20 -19 -18 -20 -22 -25 -22 -23 -23 -19 -19
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 20 19 18 20 22 25 22 23 23 19 19
Selling, General & Admin Expense		 6.04 5.52 5.04 5.54 4.94 11 4.12 4.48 4.31 3.42 3.69
Research & Development Expense		 14 13 13 15 17 14 17 18 18 16 15
Total Other Income / (Expense), net		 2.99 3.14 2.95 2.78 2.74 2.15 1.94 1.67 1.46 1.28 0.98
Interest Expense		 -2.98 -3.17 -2.95 -2.80 -2.62 -2.29 -1.94 -1.69 -1.48 -1.23 -0.98
Income Tax Expense		 0.00 -0.00 0.00 -16 0.07 -0.00 -2.20 0.01 -0.01 0.03 0.00
Basic Earnings per Share		 ($0.34) ($0.30) ($0.30) ($0.02) ($0.37) ($0.45) ($0.34) ($0.41) ($0.40) ($0.33) ($0.34)
Weighted Average Basic Shares Outstanding		 49.05M 48.01M 51.45M 51.48M 51.57M 51.58M 51.95M 52.01M 52.99M 52.54M 53.33M
Diluted Earnings per Share		 ($0.34) ($0.30) ($0.30) ($0.02) ($0.37) ($0.45) ($0.34) ($0.41) ($0.40) ($0.33) ($0.34)
Weighted Average Diluted Shares Outstanding		 49.05M 48.01M 51.45M 51.48M 51.57M 51.58M 51.95M 52.01M 52.99M 52.54M 53.33M
Weighted Average Basic & Diluted Shares Outstanding		 51.16M 51.44M 51.44M 51.52M 51.75M 51.93M 51.95M 52.99M 53.21M 53.33M 53.33M

Annual Cash Flow Statements for PMV Pharmaceuticals

This table details how cash moves in and out of PMV Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 6.52 43 288 -188 -64 -71 2.35 -2.89
Net Cash From Operating Activities		 -15 -22 -33 -47 -64 -56 -51 -74
Net Cash From Continuing Operating Activities		 -15 -22 -33 -47 -64 -56 -51 -74
Net Income / (Loss) Continuing Operations		 -18 -25 -34 -58 -73 -69 -59 -78
Consolidated Net Income / (Loss)		 -18 -25 -34 -58 -73 -69 -59 -78
Depreciation Expense		 0.34 0.39 0.32 0.31 0.32 1.26 1.14 0.13
Amortization Expense		 0.32 0.06 0.15 0.55 -0.63 -5.39 -5.37 -2.77
Non-Cash Adjustments To Reconcile Net Income		 1.07 0.92 2.08 6.30 10 12 13 5.89
Changes in Operating Assets and Liabilities, net		 0.64 1.92 -0.85 4.12 -0.57 5.43 -1.59 0.91
Net Cash From Investing Activities		 22 3.23 28 -144 -1.37 -51 53 70
Net Cash From Continuing Investing Activities		 22 3.23 28 -145 -1.37 -51 53 70
Purchase of Property, Plant & Equipment		 -0.45 -0.11 -0.15 -2.74 -7.98 -0.97 -0.66 -0.03
Purchase of Investments		 -49 -43 -15 -257 -229 -221 -148 -88
Sale of Property, Plant & Equipment		 - - - - 0.00 0.00 0.25 0.03
Sale and/or Maturity of Investments		 71 47 43 115 236 171 202 158
Net Cash From Financing Activities		 0.00 62 293 2.02 0.96 36 0.31 0.51
Net Cash From Continuing Financing Activities		 0.00 62 293 2.02 0.96 36 0.31 0.51
Issuance of Preferred Equity		 0.00 62 70 0.00 0.00 0.00 0.00 0.00
Issuance of Common Equity		 0.00 0.00 223 2.02 0.96 36 0.31 0.51
Effect of Exchange Rate Changes		 - - - 0.00 0.00 0.03 -0.04 0.01
Cash Income Taxes Paid		 0.00 0.01 0.01 0.02 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for PMV Pharmaceuticals

This table details how cash moves in and out of PMV Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -16 -14 9.95 0.87 0.28 -8.76 10 -7.21 -7.79 1.65 1.15
Net Cash From Operating Activities		 -16 -12 -16 -1.60 -17 -17 -18 -18 -20 -17 -20
Net Cash From Continuing Operating Activities		 -16 -12 -16 -1.60 -17 -16 -18 -18 -20 -17 -20
Net Income / (Loss) Continuing Operations		 -17 -16 -15 -1.21 -19 -23 -17 -21 -21 -18 -18
Consolidated Net Income / (Loss)		 -17 -16 -15 -1.21 -19 -23 -17 -21 -21 -18 -18
Depreciation Expense		 0.36 0.36 0.36 0.37 0.37 0.04 0.04 0.03 0.03 0.03 0.03
Amortization Expense		 -1.84 -1.88 -1.63 -1.38 -1.24 -1.13 -0.84 -0.72 -0.69 -0.51 -0.39
Non-Cash Adjustments To Reconcile Net Income		 3.23 2.88 2.53 2.67 2.07 6.24 1.51 1.69 1.39 1.31 1.37
Changes in Operating Assets and Liabilities, net		 -0.76 2.31 -2.17 -2.05 1.18 1.45 -1.54 1.91 0.52 0.01 -2.66
Net Cash From Investing Activities		 -34 -2.59 26 2.32 17 7.74 29 11 12 18 21
Net Cash From Continuing Investing Activities		 -34 -2.59 26 2.33 17 7.74 29 11 12 18 21
Purchase of Property, Plant & Equipment		 -0.04 -0.20 -0.60 0.00 -0.00 -0.06 -0.00 -0.01 0.00 -0.02 0.00
Purchase of Investments		 -58 -33 -30 -41 -39 -38 -16 -31 -20 -21 -11
Sale and/or Maturity of Investments		 24 31 57 43 56 45 44 42 32 40 32
Net Cash From Financing Activities		 33 0.29 0.00 0.14 - 0.17 0.01 0.10 - 0.39 0.00
Net Cash From Continuing Financing Activities		 33 0.29 0.00 0.14 - 0.17 0.01 0.10 - 0.39 0.00
Other Financing Activities, net		 - - 0.00 - - - 0.01 - - - 0.00
Effect of Exchange Rate Changes		 - 0.03 -0.03 0.01 0.00 -0.01 0.01 -0.00 0.00 -0.00 0.00

Annual Balance Sheets for PMV Pharmaceuticals

This table presents PMV Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 103 366 332 270 252 191 117
Total Current Assets		 102 365 301 247 207 176 115
Cash & Equivalents		 73 361 172 108 38 41 38
Short-Term Investments		 28 0.00 125 133 165 129 75
Prepaid Expenses		 0.61 3.34 3.30 5.13 3.53 6.20 2.28
Plant, Property, & Equipment, net		 0.74 0.57 3.09 11 11 0.41 0.24
Total Noncurrent Assets		 0.20 0.20 27 12 34 15 1.10
Other Noncurrent Operating Assets		 0.20 0.20 10 9.85 8.57 1.38 1.10
Total Liabilities & Shareholders' Equity		 103 366 332 270 252 191 117
Total Liabilities		 4.57 6.41 23 24 26 15 12
Total Current Liabilities		 4.52 6.41 12 11 14 14 11
Accounts Payable		 2.84 1.61 3.19 3.00 3.24 6.58 3.16
Accrued Expenses		 1.69 4.80 8.63 7.31 9.94 7.44 7.86
Other Current Liabilities		 - 0.00 0.40 0.53 0.85 0.35 0.40
Total Noncurrent Liabilities		 0.05 0.00 11 13 12 0.84 0.44
Other Noncurrent Operating Liabilities		 0.05 0.00 11 13 12 0.84 0.44
Commitments & Contingencies		 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -70 359 309 246 226 176 105
Total Preferred & Common Equity		 -70 359 309 246 226 176 105
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -70 359 309 246 226 176 105
Common Stock		 4.97 469 476 488 535 545 551
Retained Earnings		 -75 -110 -168 -241 -310 -369 -446
Accumulated Other Comprehensive Income / (Loss)		 -0.00 0.00 -0.08 -0.45 0.22 0.14 0.08

Quarterly Balance Sheets for PMV Pharmaceuticals

This table presents PMV Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 261 237 238 223 171 153 134 97
Total Current Assets		 205 202 219 190 163 145 132 96
Cash & Equivalents		 52 48 49 49 51 44 36 39
Short-Term Investments		 150 150 164 134 109 98 93 54
Prepaid Expenses		 2.56 3.70 5.05 5.96 3.11 3.04 3.20 2.23
Plant, Property, & Equipment, net		 11 11 11 10 0.38 0.29 0.26 0.20
Total Noncurrent Assets		 45 24 8.22 24 6.73 7.26 1.14 0.58
Other Noncurrent Operating Assets		 8.73 8.39 8.22 8.65 1.30 1.23 1.14 0.58
Total Liabilities & Shareholders' Equity		 261 237 238 223 171 153 134 97
Total Liabilities		 23 24 23 26 11 12 13 8.60
Total Current Liabilities		 11 12 11 14 9.76 12 12 8.60
Accounts Payable		 1.68 0.86 4.53 2.06 3.59 2.60 3.40 1.63
Accrued Expenses		 9.04 10 5.70 10 5.80 8.63 8.52 6.67
Other Current Liabilities		 0.00 0.88 1.15 1.24 0.36 0.38 0.39 0.29
Total Noncurrent Liabilities		 13 12 12 12 0.74 0.64 0.54 0.00
Other Noncurrent Operating Liabilities		 13 12 12 12 0.74 0.64 0.54 0.00
Commitments & Contingencies		 - - - - - - - 0.00
Total Equity & Noncontrolling Interests		 238 213 214 198 160 141 121 88
Total Preferred & Common Equity		 238 213 214 198 160 141 121 88
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 238 213 214 198 160 141 121 88
Common Stock		 532 538 541 543 546 548 549 552
Retained Earnings		 -294 -325 -326 -346 -386 -407 -428 -464
Accumulated Other Comprehensive Income / (Loss)		 -0.36 -0.13 -0.19 0.41 0.08 0.02 0.09 -0.02

Annual Metrics And Ratios for PMV Pharmaceuticals

This table displays calculated financial ratios and metrics derived from PMV Pharmaceuticals' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 44,773,748.00 45,380,354.00 45,665,428.00 51,157,636.00 - 53,211,507.00
DEI Adjusted Shares Outstanding		 0.00 0.00 44,773,748.00 45,380,354.00 45,665,428.00 51,157,636.00 - 53,211,507.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -0.77 -1.27 -1.61 -1.35 - -1.46
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -43.78% -32.14% -64.57% -35.64% -9.05% -6.45% 0.93%
EBIT Growth		 0.00% -41.16% -31.68% -64.81% -33.08% -4.13% -6.66% -0.89%
NOPAT Growth		 0.00% -41.00% -31.18% -66.83% -32.16% -4.01% -6.63% -0.89%
Net Income Growth		 0.00% -44.55% -35.85% -67.96% -26.75% 5.94% 14.87% -32.42%
EPS Growth		 0.00% -43.47% 71.26% 46.67% -25.78% 10.56% 20.83% -29.82%
Operating Cash Flow Growth		 0.00% -45.37% -48.38% -42.25% -36.91% 12.71% 7.86% -43.48%
Free Cash Flow Firm Growth		 0.00% 0.00% -61.25% -45.99% -68.41% 18.06% -10.94% -5.40%
Invested Capital Growth		 0.00% 0.00% 23.98% -175.40% 126.15% -322.99% -95.32% -14.05%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -15.19% -4.77% 1.40% -6.99% 7.02%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -15.17% -3.91% 2.74% -7.94% 6.60%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -15.84% -3.62% 2.74% -7.91% 6.43%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -15.83% -1.36% 4.95% -14.08% 6.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -140.25% -1.26% 7.69% -15.15% 7.50%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -18.82% -3.83% -5.45% 5.50% -9.80% -0.72%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -11.20% 7.49% -0.72% -3.92%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% -198.07% 9.45% -181.63% -748.06% 0.24%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.02% 100.03% 100.02% 100.04% 99.99% 100.00% 78.48% 97.28%
Interest Burden Percent		 92.90% 95.12% 98.14% 100.00% 95.29% 86.06% 87.53% 92.70%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -25.75% -15.05% -17.33% -26.44% -29.24% -29.23% -55.37%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -3,736.99% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% 18.43% -9.50% -17.33% -26.44% -29.24% -29.23% -55.37%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 35.97% -9.59% -18.75% -29.80% 0.00% -33.34% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -19 -24 -41 -54 -56 -60 -60
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -13.22% -4.31% -5.04% -6.93% -5.43% 0.54% -11.75%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -21.92% -24.85% -33.97% -57.63%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -19 -27 -35 -58 -77 -80 -85 -86
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -26 -35 -57 -77 -84 -90 -89
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 7.67 3.40 1.61 0.70 0.44 0.64
Price to Tangible Book Value (P/TBV)		 0.00 0.00 7.67 3.40 1.61 0.70 0.44 0.64
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 92.29 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.03 -1.01 -1.01 -1.01 -1.00 -1.03 -1.06
Leverage Ratio		 0.00 1.05 1.02 1.04 1.09 1.11 1.10 1.10
Compound Leverage Factor		 0.00 1.00 1.01 1.04 1.03 0.95 0.97 1.02
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 171.58% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -71.58% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 27.04 258.23 27.10 8.68 1.75 -0.08 -3.37
Noncontrolling Interest Sharing Ratio		 0.00% 171.58% 36.92% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 0.00 22.57 56.91 24.66 22.80 14.78 12.22 10.09
Quick Ratio		 0.00 22.44 56.38 24.32 22.25 14.47 11.79 9.89
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -16 -25 -37 -62 -51 -56 -59
Operating Cash Flow to CapEx		 -3,357.96% -20,243.12% -22,120.95% -1,699.67% -798.60% -5,749.69% -12,693.56% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 0.00 -3.03 -2.30 -6.34 1.66 -3.70 -7.22 -8.23
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -3.03 0.73 -4.04 7.99 -5.35 -3.52 -1.01
Enterprise Value (EV)		 0.00 279 2,393 733 153 -71 -105 -46
Market Capitalization		 212 212 2,754 1,048 397 159 78 67
Book Value per Share		 $0.00 ($23.22) $8.02 $6.80 $5.39 $4.41 $3.40 $1.97
Tangible Book Value per Share		 $0.00 ($23.22) $8.02 $6.80 $5.39 $4.41 $3.40 $1.97
Total Capital		 0.00 98 359 309 246 226 176 105
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -101 -361 -315 -244 -229 -183 -113
Capital Expenditures (CapEx)		 0.45 0.11 0.15 2.74 7.98 0.97 0.40 -0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.92 -3.07 -8.92 -5.70 -10 -8.17 -9.13
Debt-free Net Working Capital (DFNWC)		 0.00 98 358 289 236 193 161 104
Net Working Capital (NWC)		 0.00 98 358 289 236 193 161 104
Net Nonoperating Expense (NNE)		 4.31 6.71 9.98 17 19 13 -1.10 17
Net Nonoperating Obligations (NNO)		 0.00 -101 -361 -315 -244 -229 -183 -113
Total Depreciation and Amortization (D&A)		 0.66 0.45 0.47 0.86 -0.31 -4.13 -4.23 -2.64
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.40) ($1.28) ($1.61) ($1.44) ($1.14) ($1.48)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 44.78M 45.45M 45.59M 48.01M 51.58M 52.54M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.40) ($1.28) ($1.61) ($1.44) ($1.14) ($1.48)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 44.78M 45.45M 45.59M 48.01M 51.58M 52.54M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($2.40) ($1.28) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 14.36M 45.14M 45.77M 51.44M 51.93M 53.33M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -19 -24 -41 -54 -56 -60 -60
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for PMV Pharmaceuticals

This table displays calculated financial ratios and metrics derived from PMV Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 48,454,582.00 51,157,636.00 51,443,488.00 51,443,488.00 51,519,751.00 - 51,933,604.00 51,952,680.00 52,990,864.00 53,211,507.00 53,329,392.00
DEI Adjusted Shares Outstanding		 48,454,582.00 51,157,636.00 51,443,488.00 51,443,488.00 51,519,751.00 - 51,933,604.00 51,952,680.00 52,990,864.00 53,211,507.00 53,329,392.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.34 -0.31 -0.30 -0.02 -0.37 - -0.34 -0.41 -0.40 -0.34 -0.34
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -8.16% 4.88% 11.39% -2.32% -7.22% -28.62% -14.77% -11.31% -2.55% 24.91% 13.40%
EBIT Growth		 -1.35% 10.05% 15.06% -0.32% -10.92% -33.16% -18.34% -13.41% -3.57% 23.55% 11.80%
NOPAT Growth		 -1.31% 10.68% 15.17% -0.24% -11.51% -33.16% -18.35% -13.43% -2.90% 23.55% 11.80%
Net Income Growth		 8.72% 18.55% 20.17% 93.04% -15.54% -45.98% -14.18% -1,648.56% -9.53% 21.58% -3.45%
EPS Growth		 15.00% 28.57% 28.57% 94.74% -8.82% -50.00% -13.33% -1,950.00% -8.11% 26.67% 0.00%
Operating Cash Flow Growth		 6.56% 21.14% -7.81% 87.61% -7.54% -37.87% -12.86% -1,045.31% -17.70% -3.17% -7.74%
Free Cash Flow Firm Growth		 36.56% 65.45% 38.50% -22.46% -44.61% -78.90% 8.36% 53.23% 47.00% 11.65% -27.06%
Invested Capital Growth		 -186.66% -322.99% 0.00% 130.91% 35.14% -95.32% -374.36% -1,441.64% -869.57% -14.05% 2.34%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -1.92% 3.27% 4.55% -8.74% -6.80% -16.04% 14.83% -5.44% 1.61% 15.03% 1.78%
EBIT Q/Q Growth		 2.47% 3.68% 3.60% -10.78% -7.83% -15.63% 14.32% -6.15% 1.53% 14.66% 1.15%
NOPAT Q/Q Growth		 2.46% 3.70% 3.60% -10.70% -8.52% -14.99% 14.32% -6.10% 1.56% 14.57% 1.15%
Net Income Q/Q Growth		 4.57% 5.31% 3.08% 92.06% -1,485.00% -19.63% 24.19% -21.64% 0.71% 14.35% -0.01%
EPS Q/Q Growth		 10.53% 11.76% 0.00% 93.33% -1,750.00% -21.62% 24.44% -20.59% 2.44% 17.50% -3.03%
Operating Cash Flow Q/Q Growth		 -21.38% 22.82% -33.92% 90.13% -953.75% 1.06% -9.63% -0.20% -8.29% 13.27% -14.49%
Free Cash Flow Firm Q/Q Growth		 19.24% 27.80% -46.58% -43.29% 4.64% 10.68% 24.92% 26.87% -8.08% -48.88% -7.97%
Invested Capital Q/Q Growth		 29.35% -181.63% 67.39% 147.63% -248.26% -748.06% 20.80% -34.73% -7.14% 0.24% 32.18%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 99.99% 100.00% 6.98% 100.39% 100.00% 88.81% 100.02% 99.97% 100.14% 100.00%
Interest Burden Percent		 84.79% 83.37% 83.80% 86.12% 87.99% 91.39% 91.05% 92.62% 93.44% 93.61% 94.84%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -29.09% -29.24% -30.61% -22.62% -23.63% -29.23% -32.66% -45.57% -51.87% -55.37% -63.16%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -9,804.13% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -29.09% -29.24% -30.61% -22.62% -23.63% -29.23% -32.66% -45.57% -51.87% -55.37% -63.16%
Return on Equity Simple (ROE_SIMPLE)		 -30.53% 0.00% -30.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -14 -13 -13 -14 -15 -18 -15 -16 -16 -13 -13
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.16% -1.07% -2.35% 5.96% -1.78% -2.61% -1.23% -2.87% -3.23% -3.08% -3.64%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.86% -6.00% -6.59% -7.74% -10.01% -9.43% -11.39% -13.03% -12.86% -15.13%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -20 -19 -18 -20 -22 -25 -22 -23 -23 -19 -19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -20 -19 -21 -23 -26 -22 -24 -23 -20 -19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.25 0.70 0.41 0.39 0.39 0.44 0.35 0.39 0.61 0.64 0.75
Price to Tangible Book Value (P/TBV)		 1.25 0.70 0.41 0.39 0.39 0.44 0.35 0.39 0.61 0.64 0.75
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.00 -1.01 -1.00 -1.01 -1.03 -1.02 -1.02 -1.03 -1.06 -1.05
Leverage Ratio		 1.09 1.11 1.11 1.11 1.11 1.10 1.09 1.10 1.12 1.10 1.08
Compound Leverage Factor		 0.93 0.92 0.93 0.96 0.98 1.01 1.00 1.02 1.05 1.03 1.02
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 6.69 2.55 0.96 1.00 0.26 0.96 0.73 -0.48 -0.49 -1.47 -1.68
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 19.16 14.78 16.79 19.22 13.98 12.22 16.75 12.52 10.76 10.09 11.14
Quick Ratio		 18.84 14.47 16.42 18.70 13.48 11.79 16.43 12.26 10.50 9.89 10.88
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -7.88 -12 -17 -16 -14 -11 -7.74 -8.37 -12 -13
Operating Cash Flow to CapEx		 -35,588.64% -5,953.20% -2,697.33% 0.00% 0.00% 0.00% -456,650.00% -166,381.82% 0.00% -114,593.33% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.31 -3.70 -1.21 0.57 -0.85 -7.22 -5.72 -7.70 -8.25 -8.23 -5.58
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -2.83 -5.35 -1.21 2.43 0.46 -3.52 -4.51 -8.28 -7.40 -1.01 0.13
Enterprise Value (EV)		 59 -71 -126 -130 -122 -105 -109 -93 -55 -46 -27
Market Capitalization		 298 159 87 83 77 78 57 55 74 67 66
Book Value per Share		 $4.90 $4.41 $4.13 $4.17 $3.84 $3.40 $3.08 $2.71 $2.28 $1.97 $1.65
Tangible Book Value per Share		 $4.90 $4.41 $4.13 $4.17 $3.84 $3.40 $3.08 $2.71 $2.28 $1.97 $1.65
Total Capital		 238 226 213 214 198 176 160 141 121 105 88
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -239 -229 -214 -214 -199 -183 -166 -148 -129 -113 -94
Capital Expenditures (CapEx)		 0.04 0.20 0.60 -0.00 -0.03 -0.17 0.00 0.01 -0.00 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.16 -10 -8.36 -6.34 -7.61 -8.17 -6.65 -8.57 -9.11 -9.13 -6.36
Debt-free Net Working Capital (DFNWC)		 195 193 190 207 176 161 154 134 120 104 87
Net Working Capital (NWC)		 195 193 190 207 176 161 154 134 120 104 87
Net Nonoperating Expense (NNE)		 2.90 2.52 2.52 -13 3.90 5.38 2.34 5.19 5.29 4.57 4.72
Net Nonoperating Obligations (NNO)		 -239 -229 -214 -214 -199 -183 -166 -148 -129 -113 -94
Total Depreciation and Amortization (D&A)		 -1.48 -1.52 -1.27 -1.00 -0.86 -1.09 -0.80 -0.69 -0.66 -0.48 -0.35
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.30) ($0.30) ($0.02) ($0.37) ($0.45) ($0.34) ($0.41) ($0.40) ($0.33) ($0.34)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 48.01M 51.45M 51.48M 51.57M 51.58M 51.95M 52.01M 52.99M 52.54M 53.33M
Adjusted Diluted Earnings per Share		 $0.00 ($0.30) ($0.30) ($0.02) ($0.37) ($0.45) ($0.34) ($0.41) ($0.40) ($0.33) ($0.34)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 48.01M 51.45M 51.48M 51.57M 51.58M 51.95M 52.01M 52.99M 52.54M 53.33M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 51.44M 51.44M 51.52M 51.75M 51.93M 51.95M 52.99M 53.21M 53.33M 53.33M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -13 -13 -14 -15 -18 -15 -16 -16 -13 -13
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

PMV Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, PMV Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

PMV Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$77.74 million in 2025, rising from -$17.54 million in 2018. The previous period was -$58.71 million in 2024. View PMV Pharmaceuticals' forecast to see where analysts expect PMV Pharmaceuticals to go next.

PMV Pharmaceuticals' total operating income in 2025 was -$86.21 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $86.21 million

Over the last 7 years, PMV Pharmaceuticals' total revenue changed from $0.00 in 2018 to $0.00 in 2025, a change of 0.0%.

PMV Pharmaceuticals' total liabilities were at $11.85 million at the end of 2025, a 22.1% decrease from 2024, and a 159.1% increase since 2019.

In the past 6 years, PMV Pharmaceuticals' cash and equivalents has ranged from $37.71 million in 2023 to $361.42 million in 2020, and is currently $37.98 million as of their latest financial filing in 2025.

Over the last 7 years, PMV Pharmaceuticals' book value per share changed from 0.00 in 2018 to 1.97 in 2025, a change of 196.8%.


Related Companies

Financial statements for NASDAQ:PMVP last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Is the fix for AI's runaway power problem your golden ticket?
The government just committed $200 billion to building computer chips on American soil - one of the largest te...
Eagle Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
A better retirement stock than Berkshire?
Whitney Tilson - the analyst CNBC called 'The Prophet' for early calls on Netflix, Apple, and Amazon - says he...
Stansberry Research | Sponsoredtc pixel
Executive order could send gold to 6,000 per ounce
Executive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...
Cedar Gold Group | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel